MétaCan
Menu
← Back to cohort

Survival in Patients Treated with Trans Arterial Chemo Embolization (TACE) for Unresectable Hepatocellular Carcinoma and Comparison of RECIST, WHO and EASL Criteria in Determining Tumor Response

2009· article· en· W2978894006 on OpenAlexaff
Summit Sawhney, Aldo J. Montaño‐Loza, Peter Salat, Mairin McCarthy, Norman Kneteman Kneteman, Richard Owen

Bibliographic record

VenueThe American Journal of Gastroenterology · 2009
Typearticle
Languageen
FieldMedicine
TopicHepatocellular Carcinoma Treatment and Prognosis
Canadian institutionsUniversity of Alberta HospitalUniversity of Alberta
Fundersnot available
KeywordsMedicineResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaProgressive diseaseLipiodolInternal medicineRadiologyNuclear medicineChemotherapy

Abstract

fetched live from OpenAlex

Purpose: This study aims to highlight tumor response and survival in patients with unresectable hepatocellular carcinoma (HCC) receiving TACE and the correlation between RECIST, WHO, and EASL criteria in determining tumor response. Methods: We analyzed retrospectively our outcomes using TACE (doxorubicin and lipiodol) for unresectable HCC in 60 patients who were seen from January 2001 to December 2008. Demographics, presentation, etiology and treatment details were recorded for each patient. Tumors were measured in 1D, 2D and 3D (assuming spherical) and objective tumor response determined using RECIST (1D), WHO (2D) and EASL (tumor necrosis) criteria. Patients were followed until death, transplant, failure of response or treatment failure with maximum follow-up of 7 years. Results: Reporting complete data on 60 patients with 3 patients transplanted immediately post-TACE, 3 died from treatment complications and 1 lost to follow-up. Mean number of TACE per patient was 2.5±1.8 (1-8 interventions). At presentation, mean tumor diameter was 6.9±4.4 cm (1.3-20.4 cm) and 26 patients (43%) were Child-Pugh (CP) A, 25 (42%) were CP B, 1 (1.7%) was CP C and the remaining unknown. The mean MELD score was 8.5±3 points (4-17 points). Tumor response according to RECIST, WHO and EASL criteria are shown in Table 1 and most patients displayed stable disease. Overall mean survival time after first TACE was 20±2.2 months (95% CI, 11.8-26.8). Using WHO classification, mean survival in Partial Response (PR) & Stable Disease (SD) was 20.5±2.4 m (95% CI, 15.7-25.2), and in Progressive Disease (PD) was 16.9±4.4 m (95% CI, 8.4-25.5). Similar results were found using RECIST: PR & SD was 20.9±2.4 m (95% CI, 16.2-25.6), and in PD was 11.8±7.2 m (95% CI, 1.0-25.9); and EASL: PR & SD was 20.5±2.4 m (95% CI, 15.7-25.3), and in PD was 11.8±7.2 m (95% CI, 1.0-25.9). Pearson correlation coefficients between 1D, 2D and 3D measurements and between RECIST, WHO and EASL for tumor response assessment are presented in Table 2. Correlations were equally high between 1D vs. 2D, 1D vs. 3D and 2D vs. 3D measurements and concordance was best between RECIST and WHO and weakest between RECIST and WHO vs. EASL in tumor response assessment.Table 1Table 2Conclusion: TACE prolongs survival and stabilizes tumor growth in patients with unresectable HCC. Survival is better in patients who achieved PR & SD compared to patients who had PD, regardless of the classification used (WHO, RECIST or EASL). There is good concordance between 1D, 2D and 3D measurements of HCC and between RECIST and WHO criteria, but not EASL, in determining tumor response to TACE.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.272
Teacher spread0.244 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicHepatocellular Carcinoma Treatment and Prognosis→French-language works237,207→